A Phase 2 interventional study of Efgartigimod Alfa Injection and High-dose intravenous methylprednisolone in Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder and NMO Spectrum Disorder, sponsored by Tianjin Medical University General Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-11.
Sponsored by Tianjin Medical University General Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital — 5 open to participants now, 8 under way, 3 of them phase 3. Neuromyelitis Optica · Tianjin Medical University General Hospital.
Among the 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 9th registered.
178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.
Browse Neuromyelitis Optica studies →5 of the 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital are open now, in 1 country. Recruiting first, the newest first:
Tianjin Medical University General Hospital · Sites in China
Ages 18–80
Tianjin Medical University General Hospital · Sites in China
Ages 18–60
Tianjin Medical University General Hospital
Ages 18–60
Tianjin Medical University General Hospital
Ages 18+
By country, each count listing its studies:
Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 4
First in 2013; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 63 is above the median of 29 across 108 interventional studies indexed under Neuromyelitis Optica.
Median enrollment 24 across the 14 interventional studies, 34 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tianjin Medical University General Hospital is the lead sponsor of 75 studies on the registry; 31 are open to participants now.
4 of the studies in Neuromyelitis Optica by Tianjin Medical University General Hospital that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07420296Phase 3Tianjin Medical University General HospitalModified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder | 2026-12-31 |
| NCT07132398Phase 3Tianjin Medical University General HospitalSlow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD | 2027-08-31 |
| NCT05792462Tianjin Medical University General HospitalEfficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders | 2027-03-01 |
| NCT06561009Tianjin Medical University General HospitalSafety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
NMOSD is an autoimmune disease of the central nervous system that predominantly affects the spinal cord and optic nerves. The objectives of this study are to assess the efficacy and safety of FcRn antagonists (efgartigmod) for treatment of patients with neuromyelitis optica spectrum disorders during acute phase who are anti-aquaporin-4 (AQP4) antibody-positive. The potential of efgartigimod, an IgG1 Fc fragment that competes with IgG for FcRn binding, thereby lowering IgG levels, warrants further investigation as a treatment for acute neuromyelitis optica spectrum disorders attacks. This study aims to evaluate the therapeutic potential of efgartigmod in acute NMOSD attack.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive efgartigimod alpha via intravenous infusion at a dose of 10 mg/kg, each infusion lasting approximately 2 hours, on Week 0, 1, 2 and 3. Efgartigimod should be administered no later than the second day after initiation of high-dose intravenous methylprednisolone therapy. This is delivered intravenously at a dosage of 1,000 mg/day for five consecutive days, which is then reduced to 500 mg/day for the next three days, followed by 240 mg/day for another three days, and then 120 mg/day for an additional three days. Subsequently, the treatment shifts to oral prednisone, starting with 60 mg daily for seven days, then decreasing to 50 mg daily for the next seven days, followed by 40 mg daily for another seven days. Afterward, the prednisone dosage is reduced by 5 mg every two weeks until it reaches 10 mg. After Week 4, Inebilizumab to prevent relapse will be introduced according to the indication.
Drug: Efgartigimod Alfa Injection · Drug: High-dose intravenous methylprednisolone
Patients will be treated with injectable methylprednisolone sodium succinate as described in Arm A. After Week 4, Inebilizumab to prevent relapse will be introduced according to the indication.
Drug: High-dose intravenous methylprednisolone
Patients will be treated with efgartigimod alpha injection via intravenous infusion at a dosage of 10 mg/kg, with each session lasting approximately 2 hours, on Week 0, 1, 2 and 3. After Week 4, Inebilizumab to prevent relapse will be introduced according to the indication.
Drug: Efgartigimod Alfa Injection
Efgartigimod+IVMP; IVMP; Efgartigimod
Efgartigimod+IVMP; IVMP; Efgartigimod
Change in Neurological Disability - Expanded Disability Scale Score
The Kurtzke Expanded Disability Status Scale (EDSS) was developed to measure the disability status of subjects with demyelinating disease. It allows an objective quantification of the level of functioning that could be widely and reproducibly used by researchers and health care providers. The EDSS provides a total score on a scale that ranges from 0 to 10 where 0 is normal and 10 is deceased. Increasing disability is reflected in an increasing EDSS score.
Time frame: Acute nadir to week4
Change of FS score and MRC score at Week 12.
To evaluate changes in neurologic outcomes in subjects with acute attacks in subjects with AQP4-IgG antibody-positive neuromyelitis optica spectrum disorders who are treated with efgartigimod + IVMP versus IVMP alone at Week 12. The Functional System (FS) was developed to measure the function of seven systems, including visual functions (score 0-6), brainstem functions (score 0-5), pyramical functions (score 0-6), cerebellar functions (score 0-5, X is the condition that pyramidal weakness (BMRC grade 3 or worse in limb strength) or sensory deficits interfere with cerebellar testing), sensory functions (score 0-6), bowel and bladder functions (score 0-6), cerebral functions (score 0-5). Increasing disability of different functional system is reflected in an increasing FS score. Muscle Power Assessment (MRC) was developed to assess the muscle power of limbs. A score of 0-5 was used to grade the power. Increasing disability of muscle power is reflected in an decreasing MRC score.
Time frame: Baseline to week 12.
Change of EDSS score, FS score, and MRC score at Week 4 and 24.
To evaluate changes in neurologic outcomes in subjects with acute attacks in subjects with AQP4-IgG antibody-positive neuromyelitis optica spectrum disorders who are treated with efgartigimod + IVMP versus IVMP alone at Week 4 and Week 24. The EDSS score, FS score MRC score was described as in outcome 2.
Time frame: Baseline to Week 4 and Week 24.
Change of EQ-5D-5L score.
To evaluate changes in quality of life in subjects at Week 4, 12, 24.
Time frame: Baseline to Week 4, 12 and 24.
Change of high-contrast visual acuity in subjects with acute optic neuritis.
To evaluate changes in vision outcomes (High contrast visual acuity ) in subjects with acute optic neuritis post-treatment at Week 4, 12, 24.
Time frame: Baseline to Week 4, 12 and 24.
Change of OCT measurements in subjects with acute optic neuritis.
To evaluate changes in vision outcomes (OCT measures) in subjects with acute optic neuritis post-treatment at Week 4, 12, 24.
Time frame: Baseline to Week 4, 12 and 24.
The proportion of participants requiring rescue treatment during the study period.
To evaluate the proportion of subjects requiring rescue treatment during the study period.
Time frame: Baseline to Week 24.
The incidence of adverse events in the subjects during the study period.
To evaluate the safety and tolerability of efgartigimod +IVMP versus IVMP alone.
Time frame: Baseline to Week 24.
The vital signs, clinical laboratory indices, and electrocardiogram records of the subjects during the study period.
To evaluate the vital signs, clinical laboratory parameters and electrocardiograms during the study.
Time frame: Baseline to Week 24.
Change of serum total IgG levels.
To evaluate changes in serum levels of total IgG in participants post-treatment at Week 4, 12, 24.
Time frame: Baseline to Week 4, 12 and 24.
Change of serum AQP4-IgG antibody levels.
To evaluate changes in serum levels of AQP4-IgG antibodies in participants post-treatment at Week 4, 12, 24.
Time frame: Baseline to Week 4, 12 and 24.
Change of serum GFAP and NfL.
To evaluate changes in serum GFAP and NfL levels in participants after treatment at Week 4, 12 and 24.
Time frame: Baseline to Week 4, 12 and 24.
Change of the size and extent of MRI lesions.
To evaluate changes in spinal cord imaging in participants with acute myelitis following a course of efgartigimod + IVMP versus IVMP alone at Week 4, 12 and 24.
Time frame: Baseline to Week 4, 12 and 24.
No study locations are listed for this record.
Start is estimated for Jul 2024; primary completion for Dec 2025, 17 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Efgartigimod alfa · Methylprednisolone
Tianjin Medical University General Hospital